万泰生物
(603392)
| 流通市值：321.41亿 | | | 总市值：321.41亿 |
| 流通股本：12.64亿 | | | 总股本：12.64亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,048,467,239.17 | 523,344,880.88 | 1,818,967,457.87 | 1,498,369,947.13 |
| 营业收入 | 1,048,467,239.17 | 523,344,880.88 | 1,818,967,457.87 | 1,498,369,947.13 |
| 二、营业总成本 | 1,176,336,681.53 | 518,061,923.75 | 2,322,416,853.65 | 1,780,002,318.88 |
| 营业成本 | 378,374,030.4 | 157,747,644.58 | 921,826,885.82 | 695,514,313.91 |
| 税金及附加 | 15,801,893.41 | 5,218,761.55 | 21,478,347.15 | 13,204,225.16 |
| 销售费用 | 315,515,504.38 | 144,738,840.12 | 445,674,238.13 | 347,802,633.94 |
| 管理费用 | 196,450,358.62 | 95,242,406.83 | 384,010,208.9 | 289,303,494.75 |
| 研发费用 | 261,094,484.8 | 109,793,036.51 | 560,796,914.39 | 445,519,959.69 |
| 财务费用 | 9,100,409.92 | 5,321,234.16 | -11,369,740.74 | -11,342,308.57 |
| 其中:利息费用 | 3,329,023.88 | 1,577,407.31 | 6,457,746.22 | 5,149,053.08 |
| 其中:利息收入 | 20,610,989.81 | 8,151,517.09 | 32,898,979.54 | 17,628,843.51 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 10,324,525.44 | 5,629,422.24 | 48,297,071.98 | 23,076,254.44 |
| 加:投资收益 | 32,602,360.45 | 14,724,694.43 | 66,215,195.97 | 66,510,992.9 |
| 资产处置收益 | -1,418,439.81 | 26,672.57 | 60,231,327.31 | -51,055.19 |
| 资产减值损失(新) | -27,956,086.18 | -16,753,134.21 | -207,361,022.12 | -16,894,151.74 |
| 信用减值损失(新) | -37,612,306.19 | -75,460,630.32 | -21,570,698.36 | -49,990,223.77 |
| 其他收益 | 14,386,990.97 | 7,868,265.59 | 88,413,738.63 | 74,538,821.37 |
| 四、营业利润 | -137,542,397.68 | -58,681,752.57 | -469,223,782.37 | -184,441,733.74 |
| 加:营业外收入 | 3,460,533.97 | 218,074.47 | 797,030.08 | 678,368.2 |
| 减:营业外支出 | 3,381,105.84 | 1,406,012.37 | 12,459,004.12 | 8,093,057.21 |
| 五、利润总额 | -137,462,969.55 | -59,869,690.47 | -480,885,756.41 | -191,856,422.75 |
| 减:所得税费用 | -5,087,882.5 | -14,982,426.78 | -66,922,226.97 | -17,965,068.19 |
| 六、净利润 | -132,375,087.05 | -44,887,263.69 | -413,963,529.44 | -173,891,354.56 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -132,375,087.05 | -44,887,263.69 | -413,963,529.44 | -173,891,354.56 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -128,316,086.16 | -42,983,830.73 | -398,267,667.27 | -173,421,950.63 |
| 少数股东损益 | -4,059,000.89 | -1,903,432.96 | -15,695,862.17 | -469,403.93 |
| 扣除非经常损益后的净利润 | -168,880,320.92 | -64,602,901.66 | -622,669,164.2 | -307,618,892.32 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.1 | -0.03 | -0.31 | -0.14 |
| (二)稀释每股收益 | -0.1 | -0.03 | -0.31 | -0.14 |
| 九、综合收益总额 | -132,375,087.05 | -44,887,263.69 | -413,963,529.44 | -173,891,354.56 |
| 归属于母公司股东的综合收益总额 | -128,316,086.16 | -42,983,830.73 | -398,267,667.27 | -173,421,950.63 |
| 归属于少数股东的综合收益总额 | -4,059,000.89 | -1,903,432.96 | -15,695,862.17 | -469,403.93 |
| 公告日期 | 2026-08-20 | 2026-04-28 | 2026-04-21 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |